Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. is listed today as Eton Pharmaceuticals, Inc.: market value, financials and filings are on its company page.
Funding rounds
1 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Mar 2020 | $8 M | Private placement after listing | $2 to $10 million | equity | SEC | |
| Jun 2017 | $20 M | No. 1 | $10 to $50 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Eton Pharmaceuticals, Inc., its revenue in fiscal 2025 came from these product and service lines: Product Sales and Royalties $76.66 million (96%), License $3.29 million (4%).
Annual report (SEC XBRL) · Dec 2025
Eton Pharmaceuticals, Inc. had revenue of up to $1 million when it filed its newest notice of a funding round (Apr 2020).
SEC Form D (revenue range) · Apr 2020
The industry group it chose in its notices: Pharmaceuticals.
SEC Form D · Apr 2020
Products and services#
No products or services of Eton Pharmaceuticals, Inc. are on record.
Investors#
1 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Charles J. Casamento | Person | not stated | not stated | Held Series A preferred stock, director (Form 3, 2018) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 1 round above had up to 230 investors.
Largest shareholders today
Institutions holding Eton Pharmaceuticals, Inc. shares, as of Sep 30, 2026.
- EcoR1 Capital, LLC$127 M8.57%
- Opaleye Management Inc.$126 M8.46%
- BlackRock, Inc.$108 M7.27%
- Vanguard Capital Management LLC$62 M4.17%
- Nantahala Capital Management, LLC$45 M3.04%
- FMR LLC$42 M2.86%
- State Street Corp$40 M2.69%
- Geode Capital Management, LLC$39 M2.65%
- Morgan Stanley$26 M1.78%
- Oberweis Asset Management Inc/$26 M1.74%
- National Philanthropic Trust$25 M1.71%
- Marshall Wace, LLP$24 M1.59%
- Westside Investment Management, Inc.$21 M1.39%
- Woodline Partners LP$16 M1.07%
- Soleus Capital Management, L.P.$16 M1.07%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Sean Brynjelsen | Executive officer | Apr 2020 |
| William Wilson Troutman | Executive officer | Apr 2020 |
| Charles J Casamento | Director | Apr 2020 |
| Mark L Baum | Director | Apr 2020 |
| Norbert G Riedel | Director | Apr 2020 |
| Paul V Maier | Director | Apr 2020 |
| Sean Brynjelsen | Director | Apr 2020 |
| Andrew Boll | Director | Jun 2017 |
| Charles Casamento | Director | Jun 2017 |
| Mark Baum | Director | Jun 2017 |
Went public since 2018. Its SEC number is that of a company listed on a stock exchange.